MARKET

OLMA

OLMA

Olema Pharmaceuticals, Inc.
NASDAQ
23.65
+0.28
+1.20%
After Hours: 22.52 -1.13 -4.78% 19:59 02/11 EST
OPEN
23.48
PREV CLOSE
23.37
HIGH
23.78
LOW
22.40
VOLUME
1.84M
TURNOVER
--
52 WEEK HIGH
36.26
52 WEEK LOW
2.860
MARKET CAP
1.86B
P/E (TTM)
-13.0996
1D
5D
1M
3M
1Y
5Y
1D
This Olema Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday
Benzinga · 12h ago
Olema Pharmaceuticals Price Target Announced at $48.00/Share by Stifel
Dow Jones · 15h ago
Olema Pharmaceuticals Initiated at Buy by Stifel
Dow Jones · 15h ago
Stifel Initiates Coverage On Olema Pharmaceuticals with Buy Rating, Announces Price Target of $48
Benzinga · 15h ago
OLEMA PHARMACEUTICALS INC <OLMA.O>: STIFEL INITIATES COVERAGE WITH BUY RATING; PRICE TARGET $48
Reuters · 19h ago
Olema Oncology initiated with a Buy at Stifel
TipRanks · 1d ago
Weekly Report: what happened at OLMA last week (0202-0206)?
Weekly Report · 2d ago
Olema Pharmaceuticals to Join Major Biotech and Oncology Investor Conferences
Reuters · 02/04 21:30
More
About OLMA
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. It is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in a Phase 3 clinical trial called OPERA-01. It is being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In addition, it is developing OP-3136, a potent KAT6 inhibitor, in a Phase 1 clinical trial. OP-3136 is a novel, orally available small molecule that potently and selectively inhibits KAT6.

Webull offers Olema Pharmaceuticals Inc stock information, including NASDAQ: OLMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OLMA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OLMA stock methods without spending real money on the virtual paper trading platform.